Showing results (21-30 of 28) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Leukemia|April 22, 2025
Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myelomaNatalya Plakhova, Vasilios Panagopoulos, Melissa D Cantley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progressionRobert Z Orlowski, Arnon Nagler, Pieter Sonneveld, et al.Internal Medicine Journal|August 8, 2017
Bisphosphonate guidelines for treatment and prevention of myeloma bone diseaseOi Lin Lee, Noemi Horvath, Cindy Lee, et al.Haematologica|January 18, 2024
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 studySlavisa Ninkovic, Simon J Harrison, Je-Jung Lee, et al.Internal Medicine Journal|January 12, 2017
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Constantine S Tam, Douglas Joshua, et al.Internal Medicine Journal|October 19, 2021
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma AustraliaKatherine Creeper, Bradley Augustson, Kieran Kusel, et al.Journal of Hematology & Oncology|August 22, 2020
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic riskKatja Weisel, Andrew Spencer, Suzanne Lentzsch, et al.Haematologica|September 22, 2018
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTORAndrew Spencer, Suzanne Lentzsch, Katja Weisel, et al.Pageof 3